US · SLXNW
Silexion Therapeutics Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Jerusalem 9112001
- Website
- silexion.com
Price · as of 2024-12-31
$0.02
Market cap 19.3K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 |
AI valuation
Our deep-learning model estimates Silexion Therapeutics Ltd.'s (SLXNW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.02
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SLXNW | Silexion Therapeutics Ltd… | $0.02 | 19.3K | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 169.73% | 122.14% | -406.92% | -1.13 | -241.75 | 0.64 | 0.34 | -0.20 | 643590.00% | — | 8538.00% | — | -2.38 | 81.79% | — | 0.00% | — | — | — | — | — |
| ACON | Aclarion, Inc. | $2.74 | 1.59M | +1,150,885% | +444% | — | +8,000,532% | -0.01 | 0.04 | 0.77 | 0.07 | — | -0.11 | -183.81% | -12057.23% | -15293.78% | -5777.80% | 10310.16% | -305.15% | 0.00 | -10.30 | 0.71 | 0.41 | 0.07 | -9062.00% | -3936.00% | 4851.00% | -15922.34% | -4.57 | 10460.70% | 0.00% | 0.00% | 1589.28% | 0.08 | 0.07 | -9.15 | -42.51 |
| AKTX | Akari Therapeutics, Plc | $0.24 | 4.22K | — | — | — | — | 0.00 | 0.00 | — | -0.03 | 0.00 | 0.00 | 0.00% | — | — | -179.92% | -230.05% | -72.08% | 0.15 | 88.70 | 0.15 | 0.14 | -0.03 | 73000.00% | — | -2361.00% | -113611.27% | -0.63 | -133.42% | 0.00% | 0.00% | 0.00% | -0.03 | -0.05 | — | -8.66 |
| DRMA | Dermata Therapeutics, Inc… | $1.20 | 817.87K | — | — | — | — | -0.15 | 1.19 | — | 0.11 | — | 1.19 | 0.00% | — | — | -310.44% | 932.57% | -213.46% | 0.00 | — | 1.79 | 1.60 | 0.26 | -7991.00% | — | 7418.00% | -602.98% | -5.66 | 831.94% | 0.00% | 0.00% | 0.04% | 0.10 | 0.12 | — | -36.61 |
| PIII | P3 Health Partners Inc. | $2.12 | 6.93M | +1,116% | +75% | — | — | -0.09 | 0.35 | 0.02 | -0.78 | -0.11 | -0.05 | 100.00% | -21.37% | -9.05% | -284.66% | -147.86% | -37.75% | 2.19 | -14.46 | 0.37 | 0.33 | -0.64 | 7758.00% | 1848.00% | 4145.00% | -409.98% | -0.22 | -50.78% | 0.00% | 0.00% | 0.00% | -0.48 | -1.40 | 0.10 | -0.79 |
| PPBT | Purple Biotech Ltd. | $0.44 | 6.05K | +36,731% | — | — | — | -9.98 | 2.21 | — | -9.12 | -0.37 | 14.48 | 0.00% | — | — | -21.71% | -50.41% | -17.90% | 0.01 | -24.62 | 2.23 | 2.21 | 1.02 | 266250.00% | -10000.00% | -2791.00% | -19.77% | -3.60 | -65.81% | 0.00% | 0.00% | 0.00% | -5.84 | -4.48 | — | 4.27 |
| REVB | Revelation Biosciences, I… | $1.32 | 1.95M | — | — | — | — | 0.00 | 0.00 | — | 0.67 | — | 0.00 | 0.00% | — | — | -201.08% | 1657.76% | -153.82% | 0.08 | — | 5.41 | 5.36 | 0.67 | -7268.00% | — | 4498931.00% | -103262.37% | -4.14 | 1511.33% | 74316.81% | -66.80% | 198525.74% | 1.10 | 1.20 | — | -7.64 |
About Silexion Therapeutics Ltd.
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
- CEO
- Ilan Hadar
- Employees
- 11
- Beta
- -0.04
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.02) − 1 = — (DCF, example).